Coming out of the 2020 American Society of Clinical Oncology meeting, Merck & Co. Inc. is getting some credit for the potential of its TIGIT inhibitor vibostolimab, which it is studying in combination with other checkpoint inhibitors – Keytruda and a CTLA-4 inhibitor – in non-small cell lung cancer and melanoma. At least one analyst sees this candidate leading the space along with Roche’s tiragolumab, and presumably ahead of at least six other firms with anti-TIGIT agents in clinical development.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?